Modeling and Simulation: Animal health experience PAGE 2013 Glasgow UK Jonathan Mochel, Novartis Advanced Quantitative Sciences.

Slides:



Advertisements
Similar presentations
Pharmaceutical Sciences Presented by [Insert your name & title here] [Insert name of your PSMO]
Advertisements

Click to edit Master title style 1 marinescotland science Where is Sea Lice Research Required? Rob Raynard.
Biopharmaceutical Section of the American Statistical Association 1 Biopharmaceutical Section.
PAGE 2013 AHM&S Satellite Highlights Jonathan Mochel AHM&S Teleconference: September 17 th, 2013.
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Dieter Lütticken Award To stimulate the reduction of the number of animals used in development and production of veterinary medicines Busan, May 19, 2008.
What Do Toxicologists Do?
Jennifer Matysczak, VMD Leader, Aquaculture Drugs Team US Food and Drug Administration Center for Veterinary Medicine Office of New Animal Drug Evaluation.
Stefan Franzén Introduction to clinical trials.
FUTURE RESEARCH ON MALARIA: Towards a malaria-free country Emiliana Tjitra National Institute of Health Research and Development Jakarta, 30 April 2015.
Drug Discovery Exchange Fellowship Workshop 9 th -10 th December Mike Hardman IMI EMTRAIN Coordinator.
Career Opportunities in Statistics John Borkowski Montana State University Panel Discussion Pattaya Conference on Statistics Pattaya, Thailand.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Emerging infections and Health Protection In Scotland Looking to the future Kirsty Roy and Martin Donaghy Health Protection Scotland Scottish Government.
Stefan Franzén Introduction to clinical trials.
C-059-I0 EVET C-061-I0 DVEFVMPVLM A-041-N0 B-004-H0 AORTA D-115-G0 C-068-I0 UP- DMHTE.
To Fight EID, Think Global, Act Local Our response to Emerging Diseases is considered on a global basis, but implementation is regional – The risk and.
COVAB’S CENTRAL DIAGNOSTIC LABORATORY (CDL) FARMERS SEEKING FOR TECHNICAL ADVICE FROM CDL. TEAM DURING ONE OF THE EXHIBITIONS  Minimizes treatment costs.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: -relationship.
CPTR Overview CPTR 2012 Workshop October 2-4, 2012.
Fiancee Lee A. Banzon RPh.RN.  P harmacists practicing today in the Philippines or other developed or developing countries will interact with technology.
Fruit & Vegetable Production Unit for Plant Science Core Curriculum Lesson 4: Integrated Pest Management Fruit & Vegetable Production Unit for Plant Science.
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver” Elizabeth J. Phillips, MD, FRCPC,FRACP, FACTM Professor & Director, Centre for Clinical.
Prevention of infectious and parasitic diseases Dr. Wasantha Gunathunga Department of Community Medicine.
A Growing World Population
Horizon 2020 First reflections Tallinn
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Ten Years After: Where is ISAP?
Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.
GLOBAL MARKET TRENDS The view from Pharma By Peter Knauer Executive Partner, Alliance Partnership.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.
Royal Society of Chemistry Food Group Vision & Mission June 2015.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
Malaria a story of ELIMINATION A partnership of:.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.
Western Balkans Veterinary Network ‘Western Balkans Veterinary Network’- advancing animal welfare through education, research and professional training.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
Species name Disease: common name(?) Number of cases worldwide:
Higher Research Tasks Unit 4 - Immunology & Public Health
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
Multiple Model Dosage Design
Ontario Association of Bovine Practitioners November 6, 2003
RESEARCH & INNOVATION SHOWCASE Prof William Hope
بسم الله الرّحمن الرّحيم. Dr Sima Sadrai TUMS
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”
Livestock Expo and National Milk Week
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
MIDD: Perspectives and Possibilities
Royal Society of Chemistry Food Group
SRIA Roadmap Jonathan Pearce
Pharmaceutical care plans Ola Ali Nassr
Product: Division & Forum:
M-H Pinard-van der Laan
Examining the Role of Pharmacokinetics in Hemophilia
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Modeling and Simulation: Animal health experience PAGE 2013 Glasgow UK Jonathan Mochel, Novartis Advanced Quantitative Sciences

Workshop Animal Health Modeling & Simulation Society 2 | Peers Forum | J. Mochel | AHM&S PAGE 2013 The Animal Health Modeling & Simulation Society (AHM&S) is a newly founded association (2012) that aims at promoting the development, application, and dissemination of modeling and simulation techniques in the field of Veterinary Pharmacology and Toxicology The association is co-chaired by Pr. Johan Gabrielsson (Europe) and Pr. Jim Riviere (USA), and currently consists of core members from both academia and industry Half-a-day workshop with presentation of modeling applications in the animal health field: Methodological challenges with population PK in osteoarthritic dogs Optimizing antimicrobial dosage regimens with mechanistic PK/PD modeling Role of BSA and Hyperthermia on Carboplatin Dosing in Dogs M&S: A Comprehensive Tool To Streamline Drug Development Animal Health Regulatory Science Innovation Initiative (AHRSII)

Main conference AH session: PAGE plenum 3 | Peers Forum | J. Mochel | AHM&S PAGE 2013 Food safety: intersection of pharmacometrics and veterinary medicine (Pr. J Riviere) Presentation of physiological-based pharmacokinetics differences between species Inherent sources of variability for collective therapy (e.g. dose most often unknown) The application of population modeling to the calculation of residual levels and WT Two models for the control of sea lice infections using chemical treatments and biological control on farmed salmon populations (Pr. G Gettinby) Model-based approaches for capturing the infestation level of parasitized fishes Population Model integrates biological stages of the parasite and drug effect (but not T°) From epidemic to elimination: density-vague transmission and the design of mass dog vaccination programs (Pr. D Haydon) High prevalence of rabbies in developing countries (Indonesia)-child death from dog bites Simulation-based comparisons of vaccine strategies for eradicating rabbbies